Recent developments include FDA clearance for MEDIFLY Maggots, executive appointments, research collaborations, and expansion into new markets and product lines.

• Cuprina received FDA 510(k) clearance for its MEDIFLY Maggots product for wound treatment in June 2026, a key regulatory milestone that led to a stock price increase [N6][N4][S2].
• The company appointed Dr. Ronald A. Sherman as Medical and Scientific Director in July 2025, enhancing its bio-therapeutic expertise [N7].
• Cuprina advanced collagen peptide research through collaborations with Singapore institutions, supporting product development [N8].
• The company completed construction of an IVF media production facility and achieved ISO 13485 certification in Singapore, supporting quality manufacturing [N8].
• Cuprina expanded its chronic wound care offerings and entered the medicinal leech market in the MENA and GCC regions, broadening its geographic and product footprint [N8].
• Following its IPO in April 2025 and over-allotment closing in May 2025, the company raised net proceeds of approximately $10.85 million used for growth and working capital [S1].

Cuprina has achieved significant regulatory milestones including FDA clearance for its MEDIFLY Maggots product, which supports its entry into the U.S. market and validates its technology. The company has expanded its product offerings into the medicinal leech market and cosmeceutical segments, diversifying revenue streams. Strategic collaborations with research institutions and appointment of experienced medical leadership enhance its bio-therapeutic expertise and product pipeline. The company maintains a solid liquidity position with cash and current assets exceeding current liabilities, supporting ongoing operations and growth initiatives. Its IPO proceeds have been deployed to expand into new markets and invest in R&D and infrastructure, positioning it to capture growth opportunities in the chronic wound care market.

Cuprina reported a net loss of $3.63 million USD for the fiscal year ended December 31, 2025, with limited revenue of $38,789 USD, indicating ongoing operating losses and early-stage commercial traction. The company faces customer concentration risks and operates in a competitive medical device market requiring continued regulatory approvals and practitioner education. Liquidity, while currently adequate, may require enhancement if operating losses persist or if additional investments are needed. The company is exposed to risks related to credit, interest rates, and foreign exchange, although mitigated by policies and currency concentration. Market adoption of novel therapies such as maggot debridement may face challenges in acceptance and reimbursement.

Cuprina's moat is supported by its specialized focus on Maggot Debridement Therapy products, which require regulatory approvals and clinical education to gain adoption among healthcare practitioners. The company's in-house manufacturing capabilities, research collaborations, and regulatory clearances such as FDA 510(k) clearance for MEDIFLY Maggots create barriers to entry. Additionally, its ISO 13485 certified production facilities and established presence in multiple geographic markets including Southeast Asia, China, and the Middle East contribute to competitive positioning. The company's emphasis on practitioner education and training further supports customer retention and product adoption, which are critical in the medical device sector.

• Regulatory Risk: The company’s products require regulatory approvals such as FDA clearance; delays or failures in obtaining or maintaining such approvals could impact operations.
• Market Adoption Risk: Adoption of maggot debridement therapy and related products depends on healthcare practitioner education and acceptance, which may be slow or limited.
• Financial Risk: The company has reported net losses and limited revenue, which may require additional financing and could dilute shareholders or increase debt.
• Customer and Vendor Concentration: Significant revenue and accounts receivable are concentrated among a few customers and vendors, posing risks if relationships change.
• Liquidity Risk: While current liquidity ratios are adequate, ongoing losses and investment needs may pressure cash resources.
• Cybersecurity Risk: The company manages cybersecurity risks but remains exposed to potential threats that could disrupt operations or compromise data.

• Cuprina Holdings (Cayman) LTD is a holding company incorporated in the Cayman Islands, with subsidiaries operating primarily in Singapore, Malaysia, China, Hong Kong, and the United States [S1].
• The company manufactures, supplies, and sells medical devices focused on Maggot Debridement Therapy (MDT) products to manage and accelerate healing of chronic wounds, with products derived from sustainable natural bioactive sources [S1].
• Cuprina also offers cosmeceutical and nutraceutical products related to wound care [S1].
• The company operates two reportable segments: Maggot Debridement Therapy Product and Cosmeceutical Product [S1].
• Revenue is primarily generated from sales of chronic wound care products, mainly to hospitals and clinics in Singapore and Hong Kong, with a focus on educating healthcare practitioners to drive product adoption [S1].
• Cuprina completed its IPO on April 11, 2025, issuing 3 million Class A Ordinary Shares at $4.00 per share, raising net proceeds of approximately $10.85 million including an over-allotment option [S1].
• The company has used IPO proceeds for growth and expansion into new markets including Southeast Asia (excluding Singapore), Hong Kong, mainland China, and the Middle East; research and development; brand building; equipment and infrastructure investments; loan repayments; and working capital [S1].
• Cuprina has a strong focus on research collaborations, including with Singapore institutions on collagen peptide research [N8].
• The company has expanded its chronic wound care offerings and entered the medicinal leech market in the MENA and GCC regions [N8].
• Cuprina received FDA 510(k) clearance for its MEDIFLY Maggots product for wound treatment in June 2026, a significant regulatory milestone [N6][N4][S2].
• The FDA clearance led to a notable stock price increase, reflecting market recognition of this milestone [N6].
• Cuprina appointed Dr. Ronald A. Sherman as Medical and Scientific Director in July 2025, enhancing its bio-therapeutic expertise [N7].
• The company completed construction of an IVF media production facility and achieved ISO 13485 certification in Singapore, supporting quality manufacturing standards [N8].
• Financial snapshot as of December 31, 2025: cash and cash equivalents of $2.42 million USD; current assets of $5.7 million USD; current liabilities of $2.42 million USD; current ratio of 2.35; cash ratio of 1.0 [S1].
• Revenue for the fiscal year ended December 31, 2025 was $38,789 USD, with a net loss of $3.63 million USD and basic and diluted EPS of -22.83 SGD per share [S1].
• The company maintains credit risk management policies, dealing with high credit rating counterparties and monitoring receivables to minimize bad debts [S1].
• Liquidity risk is managed by maintaining adequate cash and bank balances to meet financial obligations and mitigate cash flow fluctuations [S1].
• Interest rate risk arises from borrowings and lease liabilities; the company monitors cash levels and business plans to manage this risk [S1].
• Foreign exchange risk is minimal as most transactions are in Singapore Dollars [S1].
• Cuprina has not had any defaults on indebtedness or dividend arrearages [S1].
• The company has adopted a Code of Business Conduct and Ethics and insider trading policies to promote ethical conduct and compliance [S1].
• Cybersecurity risk management includes ongoing threat monitoring, risk assessments, employee training, and oversight by the Board and audit committee; no material cybersecurity incidents have been reported [S1].
• Customer concentration is notable with several customers accounting for significant portions of revenue and accounts receivable; vendor concentration also exists but no single vendor accounts for more than 10% of accounts payable [S1].